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Anaphylaxis is a severe, life-threatening generalized hypersensitivity 
reaction. The European Anaphylaxis Registry was established to review 
and improve medical management of these patients, facilitate accurate 
comparisons between centres, highlight public health implications, and 
examine trends in treatment over time. This is replicated here in a South 
African setting. 
Methods: 
Participants comprised patients treated at Red Cross War Memorial 
Children’s Hospital (RCWMCH) for severe allergic reactions between 
January 2014 and August 2016. Recruitment was by applying relevant ICD-
10 coding to the hospital’s clinical summary system of admissions and 
discharges, the pharmacy’s records of adrenaline autoinjector dispensing, 
and referrals from the allergy department’s clinical staff. Participants who 
were screened but did not meet inclusion criteria after preliminary 
questioning and/or folder review were excluded. 156 episodes were 
analyzed. A local web-based registry was established, and used to capture 
data collected via a questionnaire in interviews at the RCWMCH Allergy 
Clinic.  
Results: 
Males, younger children, and participants of coloured ethnicity were more 
frequently affected. Skin and mucosa was most commonly involved, 
followed by respiratory and gastrointestinal upset, with cardiovascular and 
other systemic involvement occurring infrequently.  More than 40% of 
episodes were graded as severe. Specific IgE was the most frequently 
requested testing. Nearly two-thirds of patients were seen with a recurrent 
episode. Food-related triggers predominated and decreased with age: 
particularly peanut, hen’s egg, fish, cashew nuts and cows’ milk. There was 
a strong correlation with atopic conditions, in excess of international trends. 
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Adrenaline was rarely used, by both lay persons when previously 
prescribed, and by professional attenders. Hospital admissions were 
infrequent, and no deaths were recorded. Prophylactic measures were 
almost universally instituted, but the success thereof could be improved.  
Conclusion: 
This is the first local comprehensive description of anaphylactic trends. 
Further areas of research are suggested: to investigate the propensity for 
allergic reactions in the coloured population, our much higher rate of 
association with other atopic disorders compared to international patterns, 
comparison of our baseline comorbid conditions for contextual analysis, and 
a review of barriers to care. Ongoing education and training to patients, 
parents, teachers, and health care workers is identified as a major area 
requiring intensification. 
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LITERATURE REVIEW 
 
Anaphylaxis is defined as “a severe, life-threatening generalized or 
systemic hypersensitivity reaction”[1]. These are generally caused by IgE-
dependent immunological mediation, but IgE-independent mechanisms and 
direct mast cell stimulation have also been implicated, as well as idiopathic, 
and recently IgG-mediated reactions[2].  
 
Several grading systems exist to categorize anaphylactic reactions. Ring 
and Messner initially proposed a simplified classification system based on 
organ systems involved and reaction severity (Appendix A)[3]. In 2010, WAO 
described two categories of adverse effects secondary to allergen 
immunotherapy administration[4]: local reactions and systemic allergic 
reactions (SAR), ranging from mild rhinitis to multi-organ system 
involvement and fatal arrest. Grading is assessed retrospectively by the 
health care professional. Recently, a modified version was proposed[5] to 
classify SARs from any cause, taking into consideration route of 
administration of allergen, first symptoms/signs, and timing of onset of 
reaction and treatment, with the aim to allow for better safety comparisons 
across different venues and treatment protocols. The classic initial grading 
system was utilized for this project, to facilitate comparison with identical 
European studies. 
 
The World Allergy Organization (WAO)[2,6,7,8], the European Academy of 
Allergy and Clinical Immunology (EAACI)[9], the American Academy of 
Allergy, Asthma and Immunology (AAAAI), the American College of Allergy, 
Asthma and Immunology (ACAAI)[10], and the Allergy Society of South 
Africa (ALLSA)[11,12] are in consensus[13] on their recommendations for the 
assessment and management of anaphylaxis. 
• The diagnosis of anaphylaxis is primarily a clinical one, where 
optimal management is based on the early recognition of 
characteristic symptoms and signs following exposure to a likely or 
known trigger. These symptoms are usually of sudden onset, and 
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can be multi-systemic, particularly respiratory compromise, reduced 
blood pressure, signs of end-organ dysfunction, involvement of skin 
and mucosal tissue, and/or persistent gastro-intestinal upset. 
Laboratory testing, including tryptase, plays a supporting role, 
especially in ruling out differential diagnoses. Special care needs to 
be taken when diagnosing particular groups, like in the extremes of 
age and with pregnant women. 
• Triggers vary by age and geography, and over time. Patient-specific 
risk factors and individual co-factors can impact the severity of 
anaphylactic episodes. These include age, medical conditions (e.g. 
asthma, cardiovascular diseases, mast cell disorders, acute 
infection, pre-menstrual status), lifestyle entities (e.g. exercise, 
ethanol, and emotional stress) and drugs like non-steroidal anti-
inflammatories (NSAIDs), β-blockers, and ACE-inhibitors. 
• Swift emergency treatment with intramuscular (IM) adrenaline is vital, 
with repeat dosing 5-15 minutes apart as required. Emergency unit 
and personnel preparedness is advocated, in the form of a written 
and frequently rehearsed protocol. In addition, removing the trigger, 
calling for help, and positioning the patient in a supine position with 
elevation of the lower extremities are also advised. Further 
emergency care includes oxygen and airway management, 
intravenous (IV) access and fluid resuscitation, and cardiopulmonary 
resuscitation (CPR) as necessary. Second-line agents endorsed, if 
needed, are antihistamines, glucocorticoids, inhaled β2-agonist and 
inhaled adrenaline. These are echoed in ALLSA’s algorithm for 
treatment of severe anaphylactic reactions (Appendix B)[11]. Close 
frequent, preferably continuous monitoring is recommended, for at 
least four hours, but up to twenty-four hours in individuals at high risk 
for biphasic reactions. 
• The importance of long-term management with prevention of 
recurrence is emphasized. Before discharge, an emergency action 
plan, an adrenaline auto-injector if indicated, and medical 
identification are advised. Follow-up with a physician, preferably an 
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allergist/immunologist, is strongly advocated: for trigger identification, 
optimization of co-morbid medical management, comprehensive risk 
assessment, individualized risk-reduction strategies, ongoing 
education and training, and consideration of immune modulation 
therapy. In a study reviewing the outcome of such a system[14], it was 
found that more than a third of patients had an alteration in the 
diagnosis or suspected trigger after review by sub-specialists, and 
6% of patients underwent immunotherapy or desensitization in the 
long-term. This is re-iterated by Zieger et al[15], describing the 
important role of “the allergist as leaders, innovators, and educators”.  
• The need for further anaphylaxis studies and efforts at global 
partnerships are suggested, and an international research agenda is 
advised. 
 
A proposal by a pan-European conglomerate of ten participating countries 
advocates establishment of a collaborative severe allergic reaction 
database[16], to improve medical care of patients and highlight public health 
implications. Standardized information on incidence, triggering allergens, 
aggravating factors, demography and medical management was found to 
be lacking and urgently needed. Benefits would include appraisal of risk 
management strategies, identification of new allergens, clearer patient 
education regarding risk factors, motivation for food businesses modification 
and government agency preventative strategies based on results. 
 
This task proves more challenging by under-reporting and inadequate 
capturing of data in registries and by Emergency Departments.[17,18,19,20] 
This has largely been attributed to under-recognition and misdiagnosis by 
medical staff, as well as miscoding by the frequently used data capturing 
methods. An alternative suggestion to study the characteristics of patients 
with anaphylaxis is indirectly by reviewing adrenaline auto-injection 
dispensing patterns.[21,22,23,24,25] 
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Systematic reviews of epidemiological research[26,27] quote incident rates of 
anaphylaxis to be between 1.5 and 7.9 per 100 000 person years, an 
estimated 0.3% of the general population. Controversy abounds regarding 
this being a true increase compared to reports from previous years, versus 
improved recognition and recording by health care workers. Incidence 
reduces with age, with events occurring up to three times more often in the 
first four years of life. The commonest triggers are food, drugs, insect stings 
and latex, with food allergies occurring frequently in the younger patients, 
and more reactions to drugs and bee stings in the elderly. Geography plays 
a role, with higher prevalence noted in areas with less sunlight. 
Anaphylactic episodes recur in up to a third of patients, but deaths are rare: 
an estimated 0.12 – 1.06 per million patient-years. 
 
In addition to these, various case reports and series, as well as longitudinal 
retrospective cohort studies, were published over the last fifteen years. 
Factors assessed were not uniform across all publications, but included 
incidence, prevalence, risk factors, exposures, management options and 
outcomes of patients presenting at health institutions with anaphylaxis and 
severe allergic reactions, based on emergency department coding records 
or existing databases. We reviewed eight studies from the United 
Kingdom[28,29,30,31,32,33,34,35]; six from the USA[36,37,38,39,40,41],  four from a 
German-Austrian-Swiss collaboration[42,43,44,45]; two Spanish[46,47] and 
Australian[48,49]; and single published papers from Canada[50], Denmark[51] 
Turkey[52], Italy[53], Thailand[54], Puerto Rico[55], China[56], and a 10-country 
pan-European conglomerate[57]. Identical paediatric-based studies were 
also reviewed, eight from the USA[58,59,60,61,62,63,64,65], three Australian[24,66,67], 
two Israeli[68,69], and single reports from Italy[70], Chile[71], Canada[72], a 
German-Austrian-Swiss collaboration[73], Central Europe[74], Iran[75], and the 
UK[76]. To summarise: 
• Allergic diseases are common, affecting males and females of all 
ages, social classes, and ethnicities.[33,34] It represents a substantial 
burden of morbidity and health cost.[33,72] 
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• There is consensus regarding an increase in incidence, lifetime 
prevalence, and prescribing of adrenaline prescription in recent 
years.[28,30,31,32,46,48,49,62] The prevalence in the general population is 
quoted as at least 1.6% and likely higher[36]. 
• Prevalence and hospitalizations in children are increasing[39,46,60,65,67], 
as are food-related events[46,50]. 
• Hospital admissions for anaphylaxis are rising, but there is no 
increase in mortality[28,48,49], except drug-induced deaths[48]. This was 
attributed to changes in patient and personnel awareness and 
behaviors to the diagnosis and management of anaphylaxis[28]. 
• Triggers can be identified in one-third[55] to nearly 90% of 
episodes[56]. The commonest triggers identified are wasp and bee 
venom, animal proteins, legumes, and analgesic drugs, the 
frequencies of which is age-dependant[42]. In adults and the elderly, 
the commonest triggers are drugs and insects[28,44], while in children 
and adolescents it is food[28,44,47,60,61,64,73,75]. Male and black patients 
are more likely to have a food trigger[38]. 
• Concomitant disorders identified in children are asthma, allergic 
rhinitis, and eczema[44,45,61]. In adults it is cardiovascular diseases.[44] 
• Risk factors for admission includes 
o Gender: females[54], females of childbearing age[34]; only one 
study claimed anaphylaxis to be more common in boys[68]  
o Higher latitudes: noted in the southern UK[34], northern 
USA[38,39,40], southern regions of Australia[24], Italy[70], and 
reflected in Chilean children from different geographical 
demographics[71] 
o Improved socio-economic background: demonstrated in the 
UK[34], Australia[24] and Israel[68] 
o Not universally, ethnic minority groups. Increase in incidence, 
different trigger factors and occasionally severity of symptoms, 
when compared to their counterparts in certain areas: 
particularly Black patients in the USA[38,41], including the 
paediatric population[59,61,63] (with Hispanics less affected[63]); 
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non-Danish patients to certain drugs in Denmark[51]; Bedouin 
children in Southern Israel[68]; and Eurasian, Caucasian, 
Korean and Japanese in Singapore[22]. Regional variation has 
been shown in Italy[40], Australia[24,66], Chile[71] and the 
USA[39,40]. To note, when ethnicity has been looked at, 
generally the UK[29,33,34] and certain areas of the USA[37,58,65] 
have had a similar incidence across all racial groups. 
• Immediate recognition and treatment is crucial.[35,49,56,61,67,75] The 
commonest presentations are cutaneous followed by respiratory 
symptoms[54,73], then cardiovascular and gastrointestinal tract[73]. 
• Adrenaline is underused in Emergency Departments for 
anaphylaxis[41,42,43,50,53,60,62,64,72,73]. This is attributed to frequent 
misdiagnosis[50,53,62,64], and fear of adrenaline side-effects[50]. 
• Biphasic reactions can occur in more than 5% of patients, with 20% 
of those being very severe, prompting advice for longer observational 
times[56]. 
• Patients are generally not well equipped to deal with future episodes, 
and require ongoing education and public health initiatives[36,60,62]. 
These include patient-centered, as well as parent-friendly and 
school-based programmes[60,69,72,76].  
• Long-term follow up is recommended[54,67,69]. Appropriate 
interventions can improve the negative effect of allergic reactions on 
quality of life[61,69]. 
• Registries are important for epidemiological reasons, to improve 
medical understanding of the disease, as well as to address 
management issues[44,73] and comparative studies[57,72,75]. 
 
To elaborate on this, the network of severe allergic reactions (NORA), a 
collaboration between eleven European nations, recognized anaphylaxis 
research being reported differently between countries, and identified the 
need for standardized data collection to facilitate accurate comparison 
between referral centres and countries[57]. The European Anaphylaxis 
Registry was formed, collecting data from medical records using an online 
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questionnaire, from fifty-nine institutions in Germany, France, Switzerland, 
Austria, Spain, Poland, the United Kingdom, Greece, Bulgaria, Italy, and 
Ireland. Their results show food and insect bites being the most common 
triggers, and less frequently drugs. Most reactions are within thirty minutes 
of exposure, with the skin most often affected, although this varied with the 
eliciting factor. Steroids and antihistamines were the preferred treatment 
modalities, with adrenaline being used in only 13.7% to 27.6%. In children 
and adolescents[74], most incidents happened in private homes. Cow’s milk 
and hen’s egg were most frequently implicated in the first two years of life, 
hazelnut and cashews in pre-school ages, and peanuts in all children. A 
shift occurs from food- to insect- and drug-induced events in the first 
decade of life. Nearly a third of children were lay-treated, with adrenaline 
utilization trends increasing over the last few years. Intensive care 
admissions and fatal reactions were rare. This project is ongoing, with 
yearly intakes collected to analyze evolution of anaphylaxis trends. This is 
replicated here in a South African setting for this study, with review of self-
classified ethnicity as an additional factor[77]. 
 
There is remarkably limited data on anaphylaxis from the African continent. 
Most are case reports and series describing reactions to specific organisms 
(hydatid[78,79,80,81], anisakis[82], snakes[83,84], bee stings[85,86], non-biting 
midges[87]), plants[88], foods[89] (specifically mopane worms[90] and cow’s 
milk[91]), medication (ACE-inhibitors[92], snake antivenom[93], urografin[94], 
protamine sulphate[95], vancomycin[96], BCG vaccination[97,98]), blood 
transfusion[99], and in certain special circustances (in ENT[100], pregnant 
women[101], and latex in a hospital setting[102,103]). 
 
In African children, anaphylactic shock is described during surgery for a 
hydatid cyst [80], and a case of a severe anaphylaxis is described after 
exposure to a trace-amount of cow’s milk protein[91]. A cohort study looking 
at a series of severe food reactions at Red Cross Children’s Hospital 
requiring adrenaline auto-injector prescription[89] found the majority of 
patients affected were of mixed ancestry; peanut, cow’s milk and hen’s egg 
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were the most common triggers; multiple foods were frequently implicated; 
asthma is a significant risk factor; and a significant proportion of patients 
had allergic co-morbidity. 
 
Other South African studies include a review on the rationale for adrenaline 
use in anaphylaxis[104], and a consensus document by the South African 
Food Allergy Working Group, comprising the Allergy Society of South Africa 
(ALLSA), the South African Gastroenterology Society (SAGES), and the 
Association for Dietetics in South Africa (ADSA), providing local guidelines 
for the assessment, investigation and management of food allergies[12]. 
These are in keeping with international guidelines, but adapted to our 
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Anaphylaxis is a severe, life-threatening generalized hypersensitivity 
reaction. The European Anaphylaxis Registry was established to review 
and improve medical management of these patients, facilitate accurate 
comparisons between centres, highlight public health implications, and 




Participants comprised patients treated at Red Cross War Memorial 
Children’s Hospital (RCWMCH) for severe allergic reactions between 
January 2014 and August 2016. Recruitment was by applying relevant ICD-
10 coding to the hospital’s clinical summary system of admissions and 
discharges, the pharmacy’s records of adrenaline autoinjector dispensing, 
and referrals from the allergy department’s clinical staff. Participants who 
were screened but did not meet inclusion criteria after preliminary 
questioning and/or folder review were excluded. 156 episodes were 
analyzed. A local web-based registry was established, and used to capture 




Males, younger children, and participants of coloured ethnicity were more 
frequently affected. Skin and mucosa was most commonly involved, 
followed by respiratory and gastrointestinal upset, with cardiovascular and 
other systemic involvement occurring infrequently.  More than 40% of 
episodes were graded as severe. Specific IgE was the most frequently 
requested testing. Nearly two-thirds of patients were seen with a recurrent 
episode. Food-related triggers predominated and decreased with age: 
particularly peanut, hen’s egg, fish, cashew nuts and cows’ milk. There was 
a strong correlation with atopic conditions, in excess of international trends. 
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Adrenaline was rarely used, by both lay persons when previously 
prescribed, and by professional attenders. Hospital admissions were 
infrequent, and no deaths were recorded. Prophylactic measures were 
almost universally instituted, but the success thereof could be improved.  
 
Conclusion: 
This is the first local comprehensive description of anaphylactic trends. 
Further areas of research are suggested: to investigate the propensity for 
allergic reactions in the coloured population, our much higher rate of 
association with other atopic disorders compared to international patterns, 
comparison of our baseline comorbid conditions for contextual analysis, and 
a review of barriers to care. Ongoing education and training to patients, 
parents, teachers, and health care workers is identified as a major area 
requiring intensification. 
  





Anaphylaxis is “a severe, life-threatening generalized or systemic 
hypersensitivity reaction”[1] graded according to organ systems involved and 
reaction severity[2].  
 
Guidelines by the World Allergy Organization (WAO)[3], the European 
Academy of Allergy and Clinical Immunology (EAACI)[4], the American 
Academy of Allergy, Asthma and Immunology (AAAAI), the American 
College of Allergy, Asthma and Immunology (ACAAI)[5], and the Allergy 
Society of South Africa (ALLSA)[6,7] are in accord[8]: 
• Diagnosis of anaphylaxis is clinical, based on the recognition of 
characteristic symptoms and signs following exposure to a likely or 
known trigger. These include respiratory compromise, reduced blood 
pressure, signs of end-organ dysfunction, involvement of skin and 
mucosal tissue, and/or persistent gastro-intestinal upset.  
• Laboratory testing plays a supporting role, especially in ruling out 
differential diagnoses. 
• Triggers vary by age and geography, and over time.  
• Patient-specific risk factors and individual co-factors can impact the 
incidence and severity of anaphylactic episodes. 
• Swift emergency management is vital, and frequently rehearsed 
Emergency Unit protocols are advocated. Intramuscular (IM) 
adrenaline is first-line treatment[9], with repeat dosing as required. 
Removal of the trigger, calling for help, and supine positioning of the 
patient with elevation of the lower extremities is advised. Oxygen and 
airway management, intravenous (IV) access and fluid resuscitation, 
and cardiopulmonary resuscitation (CPR) needs to be instituted if 
necessary. Antihistamines, glucocorticoids, inhaled β2-agonist and 
inhaled adrenaline are the second-line agents of choice. (Appendix 
A)[6].  
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• Close frequent, preferably continuous monitoring is recommended, 
and for a prolonged period in individuals at risk for biphasic 
reactions. 
• Long-term management with prevention of recurrence is 
emphasized. This comprises issuing an emergency action plan, an 
adrenaline auto-injector if indicated, and medical identification before 
discharge. Follow-up with an allergist/immunologist is strongly 
advocated: for trigger identification, optimization of co-morbid 
medical management, comprehensive risk assessment, 
individualized risk-reduction strategies, ongoing education and 
training, and consideration of immune modulation therapy.  
• The need for further anaphylaxis studies and efforts at global 
partnerships is advised. 
 
Research in this area is generally challenging, due to under-reporting and 
low quality of captured of data in registries and by Emergency 
Departments.[10] These have largely been attributed to under-recognition 
and misdiagnosis by medical staff, as well as miscoding by the frequently 
used data capturing methods. An alternative suggestion to study the 
characteristics of patients with anaphylaxis is by reviewing adrenaline auto-
injection dispensing patterns.[11] 
 
A proposal by a pan-European conglomerate of ten participating countries 
advocates establishment of a collaborative severe allergic reaction 
database[12], to improve medical care of patients and highlight public health 
implications. Standardized information on incidence, triggering allergens, 
aggravating factors, demography and medical management was found to 
be lacking and urgently needed. Benefits include appraisal of risk 
management strategies, identification of new allergens, clearer patient 
education regarding risk factors, motivation for food businesses modification 
and government agency preventative strategies based on results. 
Facilitation of accurate comparisons between centres would also be 
optimized. 
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These Central European countries collaborated to form the network of 
severe allergic reactions (NORA). Fifty-nine institutions in Germany, 
France, Switzerland, Austria, Spain, Poland, the United Kingdom, Greece, 
Bulgaria, Italy and Ireland collectively documented data from medical 
records using an online questionnaire, as The European Anaphylaxis 
Registry[13]. This project is ongoing, with yearly updates including more 
global partners, to analyze evolution of anaphylaxis trends and treatment. 
Their review of children and adolescents[14] is replicated here in a South 
African setting. 
 
There is limited data on anaphylaxis from the African continent, and even 
less in the paediatric population: all being case reports and series 
describing reactions to specific triggers. There are no epidemiological or 
register-based African studies. With this review of our patient demographics 
and management, we plan to motivate for further locally-based, 
internationally-standardized anaphylaxis registries and research. 
 
OBJECTIVES 
• To describe patients at Red Cross War Memorial Children’s 
Hospital (RCWMCH) who experienced severe allergic reactions, 
analyze the episodes, and review their subsequent management. 
• To establish a dedicated electronic anaphylaxis database, for 
continued data collection and review after this study is 
completed. 
• To establish links with local and international bodies, to facilitate 











A retrospective case series describing and analyzing characteristics and 
management of paediatric patients treated at RCWMCH for severe allergic 
reactions and anaphylaxis over a thirty-two month period. 
 
SETTING 
RCWMCH is a dedicated paediatric hospital in Cape Town, providing 
secondary, tertiary and quaternary care to an average of 250 000 patients 
per year[15], referred from the Western Cape, the rest of South Africa, and 
across broader Africa[16]. The Division of Asthma and Allergy provides 
diagnostic and treatment services on an inpatient, outpatient and outreach 
basis, providing multi-disciplinary care with established collaborations 
between associated services, including gastroenterology, dietetics, 
dermatology, pulmonology, ophthalmology, otolaryngology and infectious 
diseases.[17] Approval was received from the UCT Human Research Ethics 
Committee (HREC), the Departmental Research Committee (DRC) and 




All children who experienced a severe allergic reaction while under 
the care of the paediatric services at RCWMCH between January 
2014 and August 2016.  
• Recruitment 
The institutional clinical summary system of admissions and 
discharges (CLINICOM) was used to detect patients meeting the 
relevant coding criteria, according to the International Statistical 
Classification of Diseases and Related Health Problems, 10th edition 
(ICD10) Version 2015[18]: 
o T78.0 (Anaphylactic shock due to adverse food reaction) 
o T78.2 (Anaphylactic shock, unspecified) 
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o T80.5 (Anaphylactic shock due to serum) 
o T88.6 (Anaphylactic shock due to adverse effect of correct 
drug or medicament properly administered) 
In addition, patients identified by the hospital pharmacy’s records of 
adrenaline autoinjector dispensing, and referrals from the allergy 
department’s clinical staff, were used to add patients missed on the 
above screening. Afflicted children lost to follow-up were traced if 
possible and re-booked for enrolment and optimization of clinical 
care. On questioning and with retrospective folder reviews, patients 
not meeting criteria for relevant reactions in the study period were 
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Prescriptions Recorded* 
EpiPen Jnr 310 





Figure. 1: Selection of Participants 
* Recorded Visits 























Lost To Follow-Up 
41 
On First Screening        63 
Folders Untraceable       26 
Patients Uncontactable  15 
Rebooked         20 
 
No Reaction   66 
     (Jan ‘14 – Aug ’16)  
Misdiagnosis/Miscoding 43 
   Eczema Flare With Trigger 
        8 
   Viral Exanthem       8 
      (passed drug challenge) 
   Atopy        5 
   Chronic Urticaria       4 
   Skin Reaction to Fish/ Seafood 
      (passed challenge)  3 
   Hereditary Angioedema 
        3 
   Eosinophilic Oesophagitis 
        2 
   Post-Gastoenteritis Lactose  
      Intolerance       1 
   Toddler’s Diarrhoea    1 
   Air Embolus       1 
   Bronchiolitis       1 
   Croup        1 
   Cold Urticaria       1 
   Non-Specific Rash      1 
   Incidental Positive Sensitivity  
      Screening       1 
   Maternal Dietary Restriction 
        1 
   Complex cardiac with seizures  
      and developmental delay 
        1 
Outgrew   24 
Did Not Attend Appointment    18 
Transferred Out  16 
     Adult Services     10 
     Secondary Care       6 
No Consent  4 
     Parent Declined       3 
     Unaccompanied by Parent  
      1 
      
Visits Recorded* 
T78.0 – 496 
T78.2 – 21 
T80.5 – 1 
T88.6 – 1 
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Face-to-face interviews with patients and parents were conducted 
with consent (Appendix B), coinciding with routine Allergy Clinic 
visits, in two collection periods: August 2016 – November 2016, and 
July 2017 – October 2017. Of the 73 patients meeting inclusion 
criteria, each child experienced between one and eight reactions in 
the time specified, amounting to 156 episodes analyzed. (Figure 2) 
 




o Utilization of a questionnaire (Appendix C) initially developed 
by NORA and validated by double-entry congruency[19], 
modified for the South African setting.  The questionnaire was 
then programmed into an online database. 
We added self-defined ethnicity, as per the latest StatsSA 
census classification[20]. Race was not included in the 
European study, but a systematic review of the literature[21] 
shows African ethnicity as a potential risk factor for fatal 
anaphylactic episodes, with limited data on the effect of race 
on non-fatal episodes.  We hope, by reviewing the interaction 
of race on different variables in our setting, particularly 


















Number of Reactions in Collection Period 
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areas of focus for potential future individual optimization of 
care. 
o Establishment of an electronic web-based registry on 
REDCap, a clinical data management system, facilitated by 
the UCT’s Clinical Research Centre, in collaboration with 
NORA and fashioned on the online data entry system used for 
the European Anaphylaxis Registry. 
• Variables 
o Demographics: age at episode, sex, ethnicity.  
o Symptomatology: range, onset, timing, fatality, location, and 
recurrence. In addition, severity was assessed by reviewing a 
composite of symptoms, based on the classification system by 
Ring and Messner.[2] (Table 1) 
o Diagnostic investigations 
o Previous diagnoses and advice 
o Eliciting triggers and dosage 
o Exacerbating factors and concomitant diseases 
o Treatment: emergency, prophylaxis, follow-up 
o Further comments (as free text) 
 








   










  (rise ≥ 20 bpm) 
Hypotension 
  (SBP drop ≥ 20 mm Hg) 
Arrhythmia 

















 Circulatory Arrest 
Table 1: Ring and Messner grading scale for anaphylactic reactions 
*according to the worst manifestation, none is obligatory 
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DATA MANAGEMENT 
Patient details were collected for initial identification purposes and informed 
consent, then numerically encrypted and utilized in this anonymous format 
for database entry and analysis. The subsequently established REDCap 
Anaphylaxis Registry was access-restricted, with only approved 





Males and younger participants were more frequently affected, with a 
significant proportion being of self-defined coloured ethnicity. The median 
age at reaction was 3.0 years (IQR 1.7 – 5.25).  
 
SYMPTOMATOLOGY 
Skin and mucosal surfaces were almost universally involved, followed by 
respiratory compromise, with gastro-intestinal upset and cardiovascular 
symptoms less common (Figure 3). Half of the instances recorded were 
classified as mild, with only 8 cases (5.1%) being Grade 2, and the 
remainder (44.9%) being Grade 3 (Table 2). Four episodes (2.6%) occurred 
with a biphasic reaction, all of them 4-12 hours after exposure. There were 
no fatalities analysed in the collection period. All reactions happened in 
South Africa, with 6 (4.5%) of cases associated with a foreign national. A 
fifth of incidences occurred secondary to a medically-supervised allergen 
challenge in a health care setting, with 65% of events occurring at home.  
 
DIAGNOSTIC TESTING 
Only 12 cases (7.7%) had no allergen identified. Skin prick testing and 
specific IgE assays were the mainstay of diagnosis, being utilized in 54.5% 
and 84.0% of reactions respectively, and being positive in nearly all tested 
(98.6% and 100%). Tryptase levels were rarely reviewed in our setting 
(4.5% of reactions). 
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 GRADE 1 GRADE 2 GRADE 3 TOTAL 






0 – 5 years 
6 – 14 years 
Ethnicity 





























































0 – 10 mins 
11 – 30 mins 
31 – 60 mins 
61 – 120 mins 
2 – 4 hrs 
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Non-Prepacked 
Food: Quantity 
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Table 2: Comparisons in Patient Severity      
 
ELICITING TRIGGERS 
Three instances (1.9%) were caused by an unknown allergen, one (0.6%) 
by drugs (ibuprofen), and the remainder by a food-related trigger (Figure 4). 
The vast majority of food reactions were caused by very small amounts of 
food ingested; 75.6% less than one teaspoon.  Of those having reactions to 
prepacked foods (88), 60 (68.2%) had the trigger in the product name or 
listed in the ingredients, in the “may contain” advice box in three cases 
(3.4%), and 25 (28.4%) could not recall the labeling. In those having 
reactions to non-prepacked foods (64), 39 (60.9%) were homemade, 20 
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Figure 4: Distribution of Eliciting Triggers 
 
EXACERBATING FACTORS 
Atopic conditions had a strong correlation with severe allergic reactions, 
with 89.7% having eczema, 85.3% allergic rhinoconjunctivitis and 67.9% 
asthma (Table 2). In 115 (72%) of instances, the patients had an associated 








4%	   4%	  
3%	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   51	  
MANAGEMENT 
First Line 
10.3% (16 of 156) of instances went untreated. A lay person was the first 
responder in 92 (59.0%) of cases. Of those managed by a lay person first, 
87 (95.6%) was a family member, usually the parent, three cases (3.3%) 
were self-managed, and one (1.1%) was a nursery school teacher. When 
primary care was managed by a professional, 37 of the 67  (55.2%) was by 
an emergency doctor or general practitioner, with the allergy specialist only 
involved in the care of 29 cases (43.3%). All allergen challenges (32 of the 
total 156, translating to 20.5%) were managed by the supervising allergy 
specialists.  
The majority of first-line lay-person treatment was antihistamine (83 of the 
92: 90,2%). Adrenaline auto-injector use in those patients previously 
prescribed (84) was rare, in 12 cases (14.3%) not being present at the time 
of the reaction, and with 40 (47.6%) available but not used. Similarly with 
previously prescribed inhaled β2-agonists (96): available and not used in 60 
(62.5%), prescribed but not available with one (1.0%); prior oral 
antihistamines prescription (139): available and not used in 19 (13.7%), 
prescribed but not available with 6 (4.3%); and with oral corticosteroids (2 
cases): prescribed and available but not used in two both (100%). These 
excludes the hospital-associated allergen challenges. 
29.4% of all professional care (20 of 68) was preceded by lay treatment. 
Adrenaline was administered as first line care by the attending health 
professional intramuscularly (12 cases, 17.6%), intravenously once, (1.5%), 
and as an inhalant (once, 1.5%) in cases managed professionally (68). 
Antihistamine orally (47 of 68, 69.1%) and inhaled β2-agonists (15 cases, 
22.1%) were the mainstay of professional treatment, with intravenous 
antihistamines and oral corticosteroid administered once each (1.5%).  
Second Line 
19 instances (13.6%) required second-line therapy, mostly oral 
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Admissions 
No patients admitted to hospital (13.5% of the total), required intensive 
care.  
Prophylaxis 
Prophylactic measures were instituted before and after the recorded 
reactions to varying degrees (Table 3). Of the 104 instances replying 
positively to Medic Alert Identification, 4 (8.7%) have applied and are still 
awaiting their bracelets, two (3.8%) had theirs stolen, in three instances 
(2.9%) it was lost, one (2.9%) was using a second one, and in eight cases 
(7.7%) the child refuses to wear them. 
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RECURRENCE 
101 (64.7%) of all episodes were preceded by a previous reaction to the 
same allergen. Of these, 36 (35.6%) had a single preceding event, 28 
(27.7%) had two, 7 (6.9%) three, 26 (25.7%) more than three, and in 4 
instances (3.96%) an unknown quantity of reactions. 89 (88.1%) of these 
preceding episodes were severe, with 37 (36.6%) recalled as milder than 
the recorded event. The commonest organ systems previously involved 
were skin (97, 96.0%) and respiratory (73, 72.3%), with gastrointestinal (18, 
17.8%) and cardiovascular (5, 5.0%) involvement being rarer.  
The allergen involved was confirmed by diagnostic testing before the 
current recorded reaction in 94 (93.0%) of these cases. 
In 106 episodes, patients were aware of an underlying allergy to the 
offending agent, this diagnosis being by a general practitioner or emergency 
physician in 22 instances (20.8%), an allergy specialist in 77 (72.6%), and 
self-diagnosed by the parent in the remaining 7 (6.6%). This 106 is slightly 
more than the number of participants who experienced a previous reaction 
(101), as some children had the current offending allergen identified as a 
potential trigger on investigation after an event following exposure to a 
different allergen. 
On review of risk reduction strategies to participants who experienced 
previous reactions, 90 of the 101 (89.1%) received advice regarding 
allergen avoidance, and 88 (87.1%) advice on management in the 
emergency situation. 94 (93%) of these participants were prescribed 
emergency drugs before the recorded episode, of these 64 (63.3%) had 
adrenaline autoinjectors, 99 (98.0%) antihistamines, 70 (69.3%) inhaled β2-
agonists, and two (2.0%) oral corticosteroids. 58 (57.4%) had a medical 





In keeping with international studies[14,21], severe allergic reactions were 
more common in males (p = 0.058) and children in the younger age groups 
(p < 0.0001). For comparison, we contrasted our findings with the European 
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Anaphylaxis Registry, who identically reviewed 1970 children from 90 
centres in ten countries. 
We had disproportionately more participants who self-classified as coloured 
affected, but no significant effect of race on severity (p = 0.428). This 
distribution could only partially be explained by socio-economic disparities 
and differing health seeking behavior between socio-demographic groups in 
Cape Town, as this coloured proportion (82.7%) was not congruent to the 
spectrum of patients seeking health care at RCWMCH for other medical 
conditions (52.0%, p < 0.0001), or the Western Cape (48.8%[22], p < 0.0001) 
and South African (8.9%[23], p < 0.0001) racial profiles.  
The pattern of systemic involvement is in keeping with global trends. The 
severity distribution differs from the European Anaphylaxis Registry[14]: 
more Grade 1 and 3 here, than Grade 2 and 3 with our counterparts. This 
could be accounted for by a lower threshold for inclusion locally, due to a 
thorough recruitment process, rather than requiring primary care doctor 
reporting to a central research agency. The timing between exposure and 
reaction is less than 10 minutes in the majority of our patients, similar to 
international studies. We recorded proportionately less biphasic reactions, 
with our patterns occurring at 4 – 12 hours after exposure, instead of the 
more than 12 hours in the NORA cohort. A comparatively larger proportion 
of our reactions happened at home. 
Diagnostic testing seemed to be used appropriately in our resource-limited 
setting, with the majority of triggers identified, an almost universal positive 
pick-up rate by the tests utilized and low rates of multiple allergen screens 
and negative results. Most diagnosis was in follow-up with the allergy sub-
specialist, in identical proportions to the above studies. Two-thirds of 
patients were noted to be allergic to the offending allergen before the 
recorded event, also similar to the European data. Almost all were advised 
regarding avoidance of the elicitor and emergency managements, but the 
practical effectiveness of this needs to be addressed, in view of the 
relatively high rate of recurrent reactions and non-use of the prescribed 
medications in the emergency situation. 
With our comparatively smaller sample size, no reactions were associated 
with insects and antibiotics, or with immunotherapy. In the European study, 
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peanuts, cows’ milk and hen’s eggs predominate as a food trigger, 
decreasing with age. Our trend is similar, with the addition of fish and tree 
nuts (particularly cashew nuts) playing a larger role, potentially due to our 
increased incidence of ingestion of the former, and possible decreased 
awareness of the latter. 
The association of allergic reactions in our population to atopic disorders 
and food hypersensitivity to a second trigger mirrors the European trend, 
but at a more than three-fold increase in rate: incidence of eczema is 89.7% 
in our participants (compared to 26.3% in the European database), allergic 
rhinitis 85.3% (21.2%), asthma 67.9% (22.9%), and food allergies to a 
different agent 73.7% (0.5%). This can only partly be explained by the 
tertiary setting of patient sampling, and opens up further suggestions for 
investigative research. The co-morbid anaemia and failure to thrive may be 
caused by highly restrictive diets in subjects with multiple food allergy. 
These prevalence rates, along with those of the neuro-developmental and -
psychiatric conditions, are difficult to interpret without a baseline population 
comparison. No other major exacerbating factors were diagnosed. 
A large proportion of all episodes were solely managed by a lay person, 
usually a parent, occasionally self administered, and rarely a teacher. This 
is in contrast to internationally, where a larger proportion was treated by 
professionals, likely due to the local under-recognition of the severity of the 
underlying condition, different health seeking behaviours and access to 
health care in our setting, and low public and school awareness of 
anaphylaxis and its management. The majority of first medical attenders 
were non-allergy specialists. Adrenaline was rarely administered, by lay 
responders and professionals. This calls for intensification of education to 
schools and emergency department staff. Fewer of our participants required 
hospital admission, likely due to the comparatively higher proportion of less 
severe reactions reviewed. Application of prophylactic measures needs 
improvement, particularly issuing of adrenaline autoinjectors in the severely 
affected group of participants and referral for Medic Alert identification. 
Education to parents and patients also requires intensification, as even 
though there was a high rate of counseling and training, still 10% of 
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reactions went untreated in the acute situation, half of which were severe. 
Investigation into barriers to treatment is also suggested. 
 
IMPLEMENTATION 
A secondary benefit of our study was identifying patients who required 
optimization of treatment, risk reduction strategies, and follow-up plans, 
addressing this as we proceeded. These included teaching and 
empowering patients and parents regarding the condition and avoidance 
measures, re-iterating advice on emergency management plans, identifying 
and addressing any gaps in knowledge, and confirming and coordinating 
follow-up appointments at appropriate institutions. 
Cooperative relations with our European colleagues at NORA were initiated, 
to contribute to the understanding of global anaphylaxis trends. We have 
also commenced collaborations between local institutions, in the form of 
discussions between the RCWMCH’s Division of Asthma and Allergy, and 
the Department of Allergology and Clinical Immunology at Groote Schuur 
Hospital, to consider replicating this study in an identical adult population. 
 
STRENGTHS AND LIMITATIONS 
This is the first locally-based, internationally-standardized review of 
anaphylaxis patterns, allowing a basis for harmonized comparisons with 
global studies. The establishment of a dedicated hospital-based registry is 
instrumental to continue long-term analysis. 
The recruitment process was systematic, as opposed to an opportunistic 
multi-centered approach, accounting for a lower threshold for inclusion 
locally. A tertiary setting for this study was appropriate, in keeping with 
recommended follow-up guidelines, but the potential for missing 
mismanaged unreferred potential participants exists. Analysis of trends over 
time was not possible due to the short study period. The study was also 
based at a single centre, resulting in a limited sample size. In addition some 
potential participants were lost-to-follow-up or excluded for other reasons.  
We analysed no fatalities, although one occurred during our collection 
period. This was due to ethical review limitation: our study was approved for 
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consent and face-to-face interviews at routine follow-up only, with doctor’s 
notes as support looking retrospectively at reactions, while the European 
Anaphylaxis Registry involved taking consent at a first visit and collecting 
data from folder reviews pro- and retrospectively for the study time 
demarcated. The reliance on parental memory might be biased, but the 
review of the associated hospital records ameliorates this. 
Additional benefits of the study were the identification and recall of patients 
who defaulted treatment, and optimization of care if management was 
deficient. The established electronic database serves as a tool for future 
data collection and review of local trends over time, as well as to facilitate 
comparative studies. Discussions were initiated locally and internationally to 




This is the first comprehensive descriptive review of local anaphylactic 
trends. In comparison to identically conducted European studies, certain 
discrepancies would benefit from further investigation: particularly the 
propensity for allergic reactions in the coloured population, as well as our 
much higher rate of association with other allergic conditions compared to 
international patterns. An analysis of our baseline comorbid disorders would 
also assist in putting the review in context, and a review of barriers to care 
would assist with patient compliance. This further serves as a motivation for 
more locally-based, internationally-standardized anaphylaxis registries and 
research. Intensification of educational efforts to patients, parents, schools, 
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APPENDIX A: ALLSA ALGORITHM  
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APPENDIX B: 
INFORMED CONSENT: INFORMATION DOCUMENT 
 
[Available in English, Afrikaans and Xhosa, to be interpreted via hospital 
translational services for other languages as necessary.] 
 
PROJECT TITLE:  
SEVERE ALLERGIC REACTIONS AT A TERTIARY PAEDIATRIC 
SERVICE 2014 – 2016 
 
PRINCIPLE INVESTIGATOR:  
Dr Sa-eeda Chippendale (0216585111) 
 
THE AIM OF THIS LEAFLET: 
• To summarize the study we are planning 
• To explain the details of how you and your child can 
participate, and what to expect 
• Our plans for the results 
• You and your child have the right to refuse to participate,  
or agree to take part now and refuse later  
• Ask any questions to assist us to help you or your child 
understand better 
• Your participation is voluntary 
 
DECRIPTION OF RESEARCH 
PURPOSE 
This research study is looking at all children presenting to Red Cross 
Hospital from 2014 with severe allergic reactions. We are asking you or 
your child to participate in providing us with information to better 
understand this condition, and potentially improve patient care for you, 
your child and other children. 
BACKGROUND INFORMATION 
Anaphylaxis is a serious, potentially life-threatening condition. There are 
no South African studies on how this affects our communities, and by 
participating in this study, you and your child are assisting us to gain 
valuable insights into this severe disorder. The aim is to utilize this 
knowledge to potentially optimize you, your child, and future children’s 
care. 
PROCEDURES 
If you or your child decide to participate, we request that the answering 
of a simple questionnaire, set up by our colleagues in Europe. 
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SUMMARY OF QUESTIONNAIRE 
We will ask about you and your child’s demographics (age, gender, 
racial profile), the symptoms of the event, if there has been previous 
episodes and advice, any associated medical conditions, triggering 
factors, treatment received, and management since then.  
DURATION 
The questionnaire would be a 30-minute interview, while the study will 










The survey will be done face-to-face at the Allergy Clinic, at the same 
time as you or your child’s scheduled clinical review, and you will incur 
no expense. There will be no compensation financially for the time you 
spend on the survey. 
 
CONFIDENTIALITY 
You or your child’s details will be collected, but stored separate to the 
questionnaires.  You and your child’s answers will be collected with other 
children’s and kept anonymous. All of our reports will have none of your 
names attached. Privacy of personal information will be an utmost 
concern, with only the captured statistical data (measurements related to 
the study) used in the write up of this report. 
 
VOLUNTARY PARTICIPATION 
You and your child’s participation is voluntary. By choosing to assist, or 
not, you and your child’s relations with the Red Cross Children’s 
Hospital, its personnel, and associated institutions, will not be affected. 
We still offer your child further training and education, optimization of 
your medication, and clarification of follow-up at an appropriate 
institution. You or your child’s participation can be withdrawn at any time. 
Both of your contributions to understanding this important condition are 
highly appreciated. 
 
FUTURE USE OF INFORMATION 
The answers you and your child provide will be collected anonymously 
and analysed by our computer. The reports, not your personal 
information, will be utilized at our Allergy Clinic by the doctors looking 
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after you and your child, and with our colleagues at Anaphylaxie: a 
European conglomerate looking at similar studies internationally. 
Stringent measures are in place to protect your personal details, and 
these will not be distributed. 
 
CONTACT DETAILS 
Feel free to contact us if there are any questions regarding consent, this 
study, the database, or Anaphylaxie: the principal investigators Dr 
Chippendale and Prof Levin at Red Cross Hospital (0216585111). If you 
feel the need to discuss you or your child’s rights as a research 
participant and your treatment by us with someone other than the 
research team, contact the UCT Human Research and Ethics 
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INFORMED CONSENT: PATIENT ASSENT (7-12 YEARS) 
 
 
Hello! We would like to speak to you and your parents 
about the time you had your allergic reaction.  
 
Your doctors are doing a research project, where we 
ask children and parents like yourself a few questions, to 
find out more about your condition and the best way to 
treat it. 
 
By answering a few questions, you can help us 
understand your illness better, and possibly help us with 
other children like you. 
 
We will keep your details private, but will share your 
answers with some other doctors also looking after 
people with this condition.  
 
You can say “No”, and your treatment at Red Cross 
Hospital will still go on like normal. 
 
¨ Yes, I’m happy to answer some questions 
 




DATE:  ________________________________ 
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INFORMED CONSENT: PATIENT CONSENT (>12 YEARS) 
 
 
If you agree with the following statements, please sign below.   
 
¨ I understand about the research, have been allowed to ask 
questions and all of my questions have been answered. 
 
¨ I agree to participate in the study. 
 
 
¨ I agree for the information gathered during the study to be 
collected and used in a database at Red Cross Hospital Allergy 
Clinic. 
 
¨ I can be contacted again when I reach the age of 18 for me to 
decide again whether I still agree for my information to be kept 





Name of Research Participant        Research Participant’s Signature 
     
 
____________________________ _____________________________ 












If you’d prefer not to take part, please do not sign, and just 
tick this box: 
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Me and my child fully understand the information provided, and my 
questions have been answered satisfactorily.  
 
¨ I hereby give consent to participate in the study. 
 
¨ I also consent for the findings of this study pertaining to myself 
or my child, to be collected and utilized in a database at Red 
Cross Hospital Allergy Clinic. 
 
¨ In addition, my child can be contacted for re-consideration of 
participation in this study, and inclusion in the database, at the 





Name of Parent/Guardian,       Parent/Guardian’s Signature 
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¨ Indian or other Asian 
¨ Other/Unspecified	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APPENDIX D: APPROVAL FORMS 
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4. HREC Topic Amendment Approval: 
 
Severe Allergic Reactions at a Tertiary Paediatric Allergy Service 
2013 – 2015 
to 
Severe Allergic Reactions at a Tertiary Paediatric Service 2014 - 
2016 
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